Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool May 25, 2005 Stephen D. Simpson	Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool July 19, 2004 W.D. Crotty	Gold Mine Cave-In? Will recalls involving the Taxus stent mar the future earnings of Boston Scientific?
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool September 26, 2005 Stephen D. Simpson	Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors?
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
The Motley Fool February 24, 2004 Alyce Lomax	J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
The Motley Fool October 14, 2005 Stephen D. Simpson	Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is.
The Motley Fool October 14, 2008 Brian Orelli	Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.
The Motley Fool July 26, 2004 W.D. Crotty	Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall.
The Motley Fool April 18, 2007 Ryan Fuhrmann	Healthy Prognosis at Johnson & Johnson The long-term prognosis for JNJ remains healthy. Investors, take note.
The Motley Fool July 13, 2004 Jeff Hwang	J&J Weathers Stent Duel The medical device and diagnostics business Johnson & Johnson delivers a solid second quarter despite competition from Boston Scientific's Taxus stent.
The Motley Fool March 17, 2009 Brian Orelli	Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace.
The Motley Fool January 26, 2011 Brian Orelli	J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool November 13, 2007 Brian Orelli	Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note.
The Motley Fool January 24, 2006 Stephen D. Simpson	Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it.
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
BusinessWeek June 18, 2007 Arlene Weintraub	Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific.
The Motley Fool October 17, 2007 Brian Orelli	J&J Puts Band-Aid on the Quarter Investors, Johnson & Johnson's earnings report reads like a one-hit wonder's second album. It goes from good to bad in the blink of an eye -- or in this case, a paragraph or so.
The Motley Fool December 8, 2004 Dave Marino-Nachison	J&J Guided to Guidant? Medical device investors felt their hearts skip as executives told The New York Times the two companies may be set to merge.
The Motley Fool July 16, 2008 Brian Orelli	J&J's Lesson to Investors: Diversify! Johnson & Johnson's second-quarter earnings report gives investors an object lesson of the benefits of the principle of diversification.
The Motley Fool June 22, 2005 Stephen D. Simpson	Stent Wars: Jury Strikes Back A jury finds that Boston Scientific has violated J&J's stent patents, but the battle is only beginning. Meanwhile, Boston Scientific continues to have market-share leadership in drug-coated stents and makes quite a bit of money from it.
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool April 19, 2005 Nathan Slaughter	Diagnosis: JNJ A-OK The health-care conglomerate beats expectations on strong international results.
The Motley Fool June 30, 2006 Stephen D. Simpson	Johnson & Johnson: This Is More Like It Filling out the drug and device businesses will be good for growth. Investors, take note.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool May 20, 2009 Brian Orelli	Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter.
BusinessWeek April 17, 2006 Amy Barrett	Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created.
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool April 29, 2011 David Williamson	Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.
BusinessWeek December 20, 2004 Amy Barrett	J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant.
The Motley Fool March 22, 2004 Seth Jayson	Stent Wars Going Strong New studies show stents do little to stop heart attacks. What does that mean for stent makers?
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool June 13, 2006 Jim Mueller	Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note.
The Motley Fool January 27, 2010 Brian Orelli	Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.
The Motley Fool January 15, 2010 Brian Orelli	The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem.
The Motley Fool February 28, 2011 Brian Orelli	Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo.